MX2020005360A - Compuestos y regimen de dosificacion para usarse en la prevencion o tratamiento de enfermedades inflamatorias cronicas y/o autoinmunes. - Google Patents

Compuestos y regimen de dosificacion para usarse en la prevencion o tratamiento de enfermedades inflamatorias cronicas y/o autoinmunes.

Info

Publication number
MX2020005360A
MX2020005360A MX2020005360A MX2020005360A MX2020005360A MX 2020005360 A MX2020005360 A MX 2020005360A MX 2020005360 A MX2020005360 A MX 2020005360A MX 2020005360 A MX2020005360 A MX 2020005360A MX 2020005360 A MX2020005360 A MX 2020005360A
Authority
MX
Mexico
Prior art keywords
treatment
prevention
chronic inflammatory
dosage regimen
autoimmune diseases
Prior art date
Application number
MX2020005360A
Other languages
English (en)
Inventor
Hella Kohlhof
Manfred Gröppel
Daniel Vitt
Andreas Mühler
Original Assignee
Immunic Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunic Ag filed Critical Immunic Ag
Publication of MX2020005360A publication Critical patent/MX2020005360A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invención se refiere a un 2-(ácido{3-fluoro-3'-metoxi- [1,1'-bifenil]-4-il}carbamoil) ciclopent-1-eno-1-carboxílico), de acuerdo con la fórmula (I),(ver formula I), y un nuevo régimen de dosificación, así como sus usos en el tratamiento de enfermedades inflamatorias crónica y/o autoinmunes. Dicho compuesto de fórmula (I) inhibe la dihidroorotato deshidrogenasa (DHODH), y es conocido por el tratamiento y la prevención de enfermedades, en particular su uso en enfermedades en las que existe una ventaja en la inhibición de la dihidroorotato deshidrogenasa (DHODH).
MX2020005360A 2017-11-23 2018-11-22 Compuestos y regimen de dosificacion para usarse en la prevencion o tratamiento de enfermedades inflamatorias cronicas y/o autoinmunes. MX2020005360A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17203407 2017-11-23
PCT/EP2018/082272 WO2019101888A1 (en) 2017-11-23 2018-11-22 Dosage regimen of vidofludimus for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases

Publications (1)

Publication Number Publication Date
MX2020005360A true MX2020005360A (es) 2020-08-13

Family

ID=60452494

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020005360A MX2020005360A (es) 2017-11-23 2018-11-22 Compuestos y regimen de dosificacion para usarse en la prevencion o tratamiento de enfermedades inflamatorias cronicas y/o autoinmunes.

Country Status (15)

Country Link
US (3) US20200360324A1 (es)
EP (1) EP3713554A1 (es)
JP (2) JP7231628B2 (es)
KR (1) KR20200090204A (es)
CN (1) CN111343975A (es)
AU (1) AU2018371177B2 (es)
BR (1) BR112020009477A2 (es)
CA (1) CA3083155A1 (es)
IL (1) IL274836A (es)
MA (1) MA50790A (es)
MX (1) MX2020005360A (es)
PH (1) PH12020550680A1 (es)
SG (1) SG11202002746YA (es)
UA (1) UA127354C2 (es)
WO (1) WO2019101888A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3892268B1 (en) * 2020-04-10 2022-08-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of vidofludimus for the treatment of coronavirus infections
CA3176008A1 (en) 2020-04-21 2021-10-28 Manfred Groppel Vidofludimus for use in the treatment or prevention of viral diseases
EP4313150A1 (en) 2021-03-26 2024-02-07 Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin Pyrimidine biosynthesis inhibitor combination for use in treating viral infections
CA3215002A1 (en) 2021-04-09 2022-10-13 Christian Gege Deuterated dhodh inhibitors
US11877994B2 (en) * 2021-08-02 2024-01-23 Immunic Ag Treatment of multiple sclerosis comprising DHODH inhibitors
TW202332433A (zh) 2021-12-23 2023-08-16 德商埃慕尼克股份公司 含羧酸生物電子等排體之dhodh抑制劑
WO2023232884A1 (en) 2022-06-01 2023-12-07 Immunic Ag Treatment of ulcerative colitis comprising vidofludimus or a pharmaceutically acceptable salt thereof
EP4389138A1 (en) 2022-12-22 2024-06-26 Cytoki Pharma ApS Dosage regimen for interleukin-22 derivatives
WO2024133936A2 (en) 2022-12-22 2024-06-27 Cytoki Pharma Aps Dosage regimen for interleukin-22 derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04000224A (es) 2001-07-10 2005-07-25 4Sc Ag Novedosos compuestos como agentes antiinflamatorios, inmunomoduladores y antiproliferativos.
TWI403506B (zh) * 2008-06-16 2013-08-01 Faes Farma Sa 用於治療急性和慢性發炎疾病之５－（４－甲磺醯基－苯基）－噻唑衍生物類
UA108760C2 (uk) 2010-07-01 2015-06-10 Кальцієві солі сполуки як протизапальні, імуномодулюючі та антипроліферативні засоби
EA201691057A1 (ru) 2013-11-22 2016-10-31 Джензим Корпорейшн Новые способы лечения нейродегенеративных заболеваний

Also Published As

Publication number Publication date
US11877995B2 (en) 2024-01-23
RU2020120536A (ru) 2021-12-23
CA3083155A1 (en) 2019-05-31
AU2018371177A1 (en) 2020-04-16
SG11202002746YA (en) 2020-04-29
JP2023057141A (ja) 2023-04-20
EP3713554A1 (en) 2020-09-30
WO2019101888A1 (en) 2019-05-31
CN111343975A (zh) 2020-06-26
AU2018371177B2 (en) 2023-10-19
US20240100005A1 (en) 2024-03-28
US20230116729A1 (en) 2023-04-13
UA127354C2 (uk) 2023-07-26
IL274836A (en) 2020-07-30
KR20200090204A (ko) 2020-07-28
BR112020009477A2 (pt) 2020-11-03
JP7231628B2 (ja) 2023-03-01
RU2020120536A3 (es) 2021-12-23
US20200360324A1 (en) 2020-11-19
MA50790A (fr) 2020-09-30
JP2021504313A (ja) 2021-02-15
PH12020550680A1 (en) 2021-03-15

Similar Documents

Publication Publication Date Title
PH12020550680A1 (en) Dosage regimen of vidofludimus for use in the prevention or treatment of chronic inflammatory and/or autoimmune diseases
EA202090955A1 (ru) Способы применения ингибиторов ehmt2 в лечении или предупреждении нарушений со стороны крови
PH12014501718A1 (en) Novel therapeutic agents
GEP20217248B (en) 2,4,5-trisubstituted 1,2,4-triazolones useful as inhibitors of dhodh
PH12017501079A1 (en) 1,3-thiazol-2-yl substituted benzamides
PH12019501802A1 (en) Compound having somatostatin receptor agonistic activity and pharmaceutical use thereof
EA201990951A1 (ru) Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение
EA201171361A1 (ru) Ингибиторы внешнего медуллярного калиевого канала почек
BR112015022197A2 (pt) tratamento de cataplexia
TR201901114T4 (tr) Özgün immünomodülatör ve anti inflamatuvar bileşikler.
TN2019000281A1 (en) Ferroportin-inhibitor salts
EA201691401A1 (ru) Индазольные соединения в качестве ингибиторов irak4
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
MX2017016424A (es) Compuestos para su uso en el tratamiento de trastornos neuromusculares.
MY196186A (en) Amino-Fluoropiperidine Derivatitves as Kinase Inhibitor
EA201290677A1 (ru) Соединения обратного амида в качестве ингибиторов протеиндеацетилазы и способы их применения
PH12018501567A1 (en) New substituted cyanoindoline derivatives as nik inhibitors
EA201590726A1 (ru) Лахинимод для уменьшения таламического поражения при рассеянном склерозе
EA201790908A1 (ru) Новые производные тиенопиримидина в качестве ингибиторов nik
EA201691402A1 (ru) Фармацевтический препарат, содержащий соединение пиридиламиноуксусной кислоты
MX2017005282A (es) Nuevos compuestos como inhibidores de la cinasa inductora de nf-kb (nik).
EA202091396A1 (ru) Композиции и способы лечения метаболических состояний
MX2020004930A (es) Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido).
MX2021007330A (es) Composiciones y métodos terapéuticos para tratar cáncer usando ácido 6, 8-bis-benciltio-octanoico y un inhibidor de autofagia.
MX2023007476A (es) Derivado de tetrahidroquinolina y uso medico del mismo.